Phathom Pharmaceuticals, Inc. (PHAT)
NASDAQ: PHAT · Real-Time Price · USD
12.63
-0.01 (-0.08%)
At close: Apr 10, 2026, 4:00 PM EDT
12.75
+0.12 (0.95%)
After-hours: Apr 10, 2026, 5:16 PM EDT
Phathom Pharmaceuticals Employees
Phathom Pharmaceuticals had 371 employees as of December 31, 2025. The number of employees decreased by 56 or -13.11% compared to the previous year.
Employees
371
Change (1Y)
-56
Growth (1Y)
-13.11%
Revenue / Employee
$471,995
Profits / Employee
-$596,353
Market Cap
1.00B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 371 | -56 | -13.11% |
| Dec 31, 2024 | 427 | -25 | -5.53% |
| Dec 31, 2023 | 452 | 340 | 303.57% |
| Dec 31, 2022 | 112 | 35 | 45.45% |
| Dec 31, 2021 | 77 | 22 | 40.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Xeris Biopharma Holdings | 435 |
| UroGen Pharma | 291 |
| KalVista Pharmaceuticals | 275 |
| Geron | 258 |
| uniQure | 221 |
| Septerna | 130 |
| ORIC Pharmaceuticals | 104 |
| Annexon | 96 |
PHAT News
- 4 days ago - Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 6 weeks ago - Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance - GlobeNewsWire
- 7 weeks ago - Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026 - GlobeNewsWire
- 2 months ago - Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026 - GlobeNewsWire
- 3 months ago - Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 3 months ago - Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 3 months ago - Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 5 months ago - Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE) - GlobeNewsWire